Company Overview - Allot Communications (ALLT) shares increased by 8% to $9.21 in the last trading session, following a period of 4.6% loss over the past four weeks, indicating a significant recovery in investor sentiment [1] - The rise in stock price is attributed to recent analyst upgrades, promising earnings potential, an expanding customer base, and effective rollout of security solutions [1] Earnings Expectations - Allot Communications is expected to report break-even quarterly earnings per share, reflecting a year-over-year change of +100% [2] - Projected revenues for the upcoming report are $22.9 million, which is a 3.3% increase from the same quarter last year [2] Stock Performance Indicators - The consensus EPS estimate for Allot Communications has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating strong market confidence [4] Industry Context - Allot Communications operates within the Zacks Technology Services industry, where Ibotta (IBTA) is another player, having experienced a 3.3% decline in the last trading session and a -26.1% return over the past month [4] - Ibotta's consensus EPS estimate has also remained unchanged, with a projected change of +113.6% year-over-year [5]

Company Overview - Personalis (PSNL) shares increased by 14.2% to $7.51 in the last trading session, with a notable trading volume, and have gained 34.6% over the past four weeks, indicating positive investor sentiment towards the company's revenue growth from pharma tests and services [1][2] Financial Performance - The upcoming quarterly report for Personalis is expected to show a loss of $0.25 per share, reflecting a year-over-year decline of 4.2%, with revenues projected at $20.2 million, down 10.5% from the same quarter last year [2] - The consensus EPS estimate for Personalis has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - Personalis operates within the Zacks Medical - Generic Drugs industry, which includes Taysha Gene Therapies, Inc. (TSHA), whose stock rose by 3.9% to $2.43 but has seen a decline of 15.8% over the past month [4] - Taysha Gene Therapies' consensus EPS estimate has increased by 12% over the past month to -$0.07, representing a year-over-year change of 22.2% [5]

Company Performance - UniFirst reported quarterly earnings of $2.17 per share, exceeding the Zacks Consensus Estimate of $2.12 per share, but down from $2.19 per share a year ago, representing an earnings surprise of +2.36% [1] - The company posted revenues of $610.78 million for the quarter ended May 2025, missing the Zacks Consensus Estimate by 0.36%, compared to $603.33 million in the same quarter last year [2] - Over the last four quarters, UniFirst has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - UniFirst shares have increased approximately 11.3% since the beginning of the year, outperforming the S&P 500's gain of 5.4% [3] - The current consensus EPS estimate for the upcoming quarter is $2.02 on revenues of $605 million, and for the current fiscal year, it is $7.94 on revenues of $2.43 billion [7] Industry Outlook - The Zacks Industry Rank indicates that the Uniform and Related industry is currently in the bottom 5% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Core Viewpoint - Progress Software (PRGS) reported quarterly earnings of $1.4 per share, exceeding the Zacks Consensus Estimate of $1.3 per share, and showing an increase from $1.09 per share a year ago, representing an earnings surprise of +7.69% [1][2] Financial Performance - The company posted revenues of $237.36 million for the quarter ended May 2025, which was slightly below the Zacks Consensus Estimate by 0.21%, but an increase from $175.08 million year-over-year [2] - Over the last four quarters, Progress Software has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - Progress Software shares have declined approximately 2.1% since the beginning of the year, while the S&P 500 has gained 5% [3] - The current Zacks Rank for Progress Software is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.31 on revenues of $240.16 million, and for the current fiscal year, it is $5.28 on revenues of $964.97 million [7] - The estimate revisions trend for Progress Software was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Computer - Software industry, to which Progress Software belongs, is currently ranked in the top 11% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Commvault Systems (CVLT), another company in the same industry, is expected to report quarterly earnings of $0.97 per share, reflecting a year-over-year change of +14.1% [9]

Group 1: Stem, Inc. (STEM) - STEM shares increased by 8.8% to $6.71 in the last trading session, following a 33.7% loss over the past four weeks [1] - The company is benefiting from a focus on high-margin software and services, particularly PowerTrack and managed services, along with cost reductions and improved operational efficiency [1] - The consensus EPS estimate for the upcoming report is a loss of $3.00 per share, reflecting a year-over-year change of +31.8%, with expected revenues of $33.1 million, down 2.7% from the previous year [2] Group 2: Earnings Estimates and Stock Performance - The consensus EPS estimate for STEM has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - STEM currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [3] - The company is part of the Zacks Computers - IT Services industry, which includes Cognizant (CTSH), also holding a Zacks Rank of 2 (Buy) [3][4] Group 3: Cognizant (CTSH) - Cognizant's consensus EPS estimate for the upcoming report has increased by 0.7% to $1.26, representing a year-over-year change of +7.7% [4] - Cognizant's stock closed the last trading session at $77.59, with a return of -4.3% over the past month [3][4]

分组1 - McCormick reported quarterly earnings of $0.69 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, with an earnings surprise of +6.15% [1] - The company posted revenues of $1.66 billion for the quarter ended May 2025, slightly missing the Zacks Consensus Estimate by 0.22%, compared to $1.64 billion in the same quarter last year [2] - Over the last four quarters, McCormick has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] 分组2 - The stock has underperformed the market, losing about 3.4% since the beginning of the year, while the S&P 500 gained 3.6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.84 on revenues of $1.71 billion, and for the current fiscal year, it is $3.02 on revenues of $6.81 billion [7] - The Zacks Industry Rank for Food - Miscellaneous is in the bottom 24% of over 250 Zacks industries, indicating potential challenges for McCormick's stock performance [8]

Core Viewpoint - General Mills reported quarterly earnings of $0.74 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $1.01 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was +4.23%, with the company having surpassed consensus EPS estimates in all four of the last quarters [2] - Revenues for the quarter were $4.56 billion, missing the Zacks Consensus Estimate by 1.04%, and down from $4.71 billion year-over-year [3] - The company has topped consensus revenue estimates twice in the last four quarters [3] Stock Performance - General Mills shares have declined approximately 16.3% year-to-date, contrasting with the S&P 500's gain of 3.6% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.94 on revenues of $4.62 billion, and for the current fiscal year, it is $3.87 on revenues of $18.95 billion [8] - The estimate revisions trend for General Mills was unfavorable prior to the earnings release, which may impact future stock performance [7] Industry Context - The Food - Miscellaneous industry, to which General Mills belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, suggesting potential challenges ahead [9] - Comparatively, Lamb Weston, another company in the same industry, is expected to report a year-over-year earnings decline of -16.7% [10]

Company Overview - Exelixis (EXEL) shares increased by 7.4% to close at $43.37, supported by high trading volume, contrasting with a 4.8% decline over the past four weeks [1] - The company announced that the late-stage STELLAR-303 study met one of its dual primary endpoints, showing a statistically significant improvement in overall survival for patients treated with zanzalintinib in combination with Tecentriq compared to regorafenib [2] - The consensus EPS estimate for Exelixis is $0.63 for the upcoming quarter, reflecting a year-over-year decrease of 25%, with expected revenues of $571.08 million, down 10.4% from the previous year [3] Earnings and Estimates - The consensus EPS estimate for Exelixis has been revised 0.8% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] - Exelixis holds a Zacks Rank of 2 (Buy), suggesting favorable market sentiment [4] Industry Context - Exelixis operates within the Zacks Medical - Biomedical and Genetics industry, where Cartesian Therapeutics, Inc. (RNAC) also competes, having closed 0.7% higher at $9.83 [4] - Cartesian Therapeutics has a consensus EPS estimate of -$0.77, representing a significant year-over-year change of -242.6%, and currently holds a Zacks Rank of 3 (Hold) [5]

Company Overview - Graham Corporation (GHM) shares increased by 7.4% to $48.40 in the last trading session, with a notable trading volume, contributing to a total gain of 22.5% over the past four weeks [1][2] Sales and Growth Drivers - The recent rally in Graham Corporation's stock is attributed to optimism regarding increased sales of capital equipment to foreign markets and higher aftermarket sales. Additionally, growth in existing programs, improved pricing, and favorable timing of key project milestones are expected to positively impact the company [2] Earnings Expectations - For the upcoming quarterly report, Graham Corporation is projected to post earnings of $0.25 per share, reflecting a year-over-year decline of 24.2%. Revenue is anticipated to reach $54 million, which is an 8.1% increase compared to the same quarter last year [3] Earnings Estimate Trends - The consensus EPS estimate for Graham has remained unchanged over the last 30 days. Historical data indicates that stock prices typically do not continue to rise without trends in earnings estimate revisions, suggesting that monitoring GHM's performance is essential to determine if the recent stock price increase can be sustained [4] Industry Context - Graham Corporation is part of the Zacks Manufacturing - General Industrial industry. Another company in the same sector, Graco Inc. (GGG), saw a 1.6% increase in its stock price, closing at $85.34, with a 0.4% return over the past month [4]

Financial Performance - Darden Restaurants reported quarterly earnings of $2.98 per share, exceeding the Zacks Consensus Estimate of $2.96 per share, and up from $2.65 per share a year ago [1] - The company posted revenues of $3.27 billion for the quarter, surpassing the Zacks Consensus Estimate by 0.18%, compared to $2.96 billion in the same quarter last year [3] - The earnings surprise for the quarter was 0.68%, while the previous quarter saw a surprise of -0.36% with actual earnings of $2.80 against an expectation of $2.81 [2] Market Performance - Darden Restaurants shares have increased approximately 19.3% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.7% [4] - The current Zacks Rank for Darden Restaurants is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.93 on revenues of $3.04 billion, and for the current fiscal year, it is $10.70 on revenues of $13.16 billion [8] - The estimate revisions trend for Darden Restaurants is mixed, and changes in earnings expectations may occur following the recent earnings report [5][7] Industry Context - The Retail - Restaurants industry, to which Darden Restaurants belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [9]